Cambridge, MA--December 1, 2016--The New Economy Magazine, a London-based publication, presented its 2016 International awards to the most innovative companies and individuals in London recently.  In describing the selection process, The New Economy says, “Our analysts look at firms and individuals that pose big questions and answer with big ideas.”

Aquinnah Pharmaceuticals was awarded “Most Innovative Neurodegenerative Research Company 2016.”  Dr. Glenn Larsen and Dr. Ben Wolozin, Co-Founders of Aquinnah, were there to receive the award.

“We are honored to have received this award and to have our work in neurodegenerative disease recognized for its groundbreaking approach.  I am very proud of our team,” said Dr. Larsen, President and CEO of Aquinnah.

Aquinnah’s program targeting the biological pathway linking persistent stress granules, aggregations of protein in the brain, and neurodegenerative disease is one of the most promising developments today and could offer amazing new hope for those suffering from ALS (amyotrophic lateral sclerosis, better known as Lou Gehrig’s disease), Alzheimer’s disease and other neurodegenerative diseases. The promise of a new therapeutic approach is especially significant after years of disappointment in ALS and Alzheimer’s research.

Currently, a diagnosis of ALS or Alzheimer’s disease leaves patients with little hope. There are no approved treatments that provide significant help. Fortunately, Aquinnah has taken a completely new approach that has the potential to arrest, and possibly even reverse, the effects of these conditions.

Both Dr. Larsen and Dr. Wolozin are very optimistic about the future of treatments for neurodegenerative disease and feel we are about to enter a golden age of therapeutic development in neurodegenerative disease.

“Aquinnah is currently the only company doing drug discovery and development on persistent stress granules.  I have great hope that we will be able to develop a drug to alleviate devastating diseases, such as ALS and Alzheimer’s disease”, said Dr. Wolozin, Chief Scientific Officer.


Aquinnah Pharmaceuticals is committed to restoring the health of people with ALS, Alzheimer’s and other neurodegenerative diseases.  They have developed a revolutionary approach that has the potential to arrest, and possibly even reverse, these diseases.

Read the editorial in the New Economy winter edition on their website:

Review the awards supplement:


Pamela Moffat